The developed radioimmunoassay for plasma thromboxane B2 is simple, sensitive, and can be used to reflect acute events involving platelet aggregation.
Answers are grounded in this paper and cite their sources.
Assay provides normative thromboxane B2 data sensitive to aspirin; leaves open clinical validation for platelet monitoring.
Platelet activity may play a major role in the acute phase of atherosclerotic cardiovascular disease. To assess such activity, an assay for plasma thromboxane B2, a prostaglandin metabolite unique to platelets, is needed. The radioimmunoassay described here is based on a nonequilibrium incubation followed by a solid-phase second-antibody separation of bound from free thromboxane B2. No prior purification is required. Values for 22 normal subjects averaged 39.0 (SD 24.6) ng/L. The thromboxane B2 concentration of a plasma sample was 20.3 ng/L as compared with 37 micrograms/L in the corresponding serum. Plasma thromboxane B2 concentrations before and after ingestion of aspirin differed significantly (p less than 0.025). The biological half-life of intravenously injected [3H]thromboxane B2 in rabbits was 20 min. At the end of 2 h, 85% of the label was accounted for in urine, 7% in liver, and 5% in lung. Our assay is simple, reproducible, sensitive, and specific. It can be used to reflect acute events involving platelet aggregation.
No takes yet. Share an insight, caveat, or question.
McCann et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: